Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology pipeline by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is an initial step toward negotiating a definitive agreement that, if completed, would grant Onco an exclusive option on Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This move could position Onco at the forefront of combining DNA damage response (DDR) therapeutics with next-generation cancer immunotherapy.
The proposed collaboration is designed to leverage Ifowonco's oral small-molecule immune checkpoint technology and Onco-Innovations' expertise in DDR therapeutics, translational oncology, and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. This is particularly noteworthy because current LAG-3 therapies are administered intravenously as monoclonal antibodies, whereas Ifowonco's program focuses on developing orally available small-molecule inhibitors, which could offer more convenient dosing and potentially improved patient compliance.
The companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its potential use alongside DDR-based therapeutic approaches, including Onco-Innovations' ONC010 program. This strategic alignment could accelerate the development of novel combination therapies that target both tumour DNA repair mechanisms and immune checkpoints.
Thomas O'Shaughnessy, CEO of Onco-Innovations, emphasized the potential of this agreement, stating that it could position the company “at the intersection of precision oncology and next-generation cancer immunotherapy.” This sentiment underscores the growing interest in combining DDR inhibitors with immune checkpoint blockade to overcome resistance and improve patient outcomes.
The news is significant because it highlights the ongoing shift toward oral small-molecule immunotherapies, which may offer advantages over existing antibody-based treatments. If successful, the collaboration could lead to new treatment options for solid tumours that are currently difficult to treat. Moreover, the exclusive option provides Onco with the flexibility to assess the program's potential before committing fully, reducing risk while retaining strategic upside.
Investors and industry observers will be watching for further developments as Onco and Ifowonco move toward a definitive agreement. The outcome of preclinical studies will be critical in determining the future of this program and its potential to make a meaningful impact in the oncology landscape.
